Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
AssigneeLife Technologies Corporation
InventorsHilde ALMAASBAK, Tanja AARVAK, Kerstin BERNSTROEM, Oystein AAMELLEM
Life of this patent
Estimating the term…
Abstract
This invention relates, inter alia, to compositions of expanded T cell populations, methods for the expansion of T cell populations and methods for using such populations of cells. In some aspects, the invention relates to compositions and methods for the selective expansion of T cell subpopulations present in mixed T cell populations, as well as T cell subpopulations produced by methods for the invention.
Claims21
1-106. (canceled)
A method for expanding regulatory T cells, the method comprising contacting the regulatory T cells with one more cytokines and stimulating the regulatory T cells with an anti-CD3 antibody and an anti-CD28 antibody, and
- wherein the regulatory T cells expand from 500 fold to 1,000 fold after 15 days post-activation.
A method for expanding antigen experienced T cells, the method comprising activating the antigen experienced T cells by contacting the antigen experienced T cells with at one or more cytokines and with an antibody combination selected from the group consisting of:
- (a) an anti-CD3 antibody and an anti-CD28 antibody,
- (b) an anti-CD3 antibody and an anti-CD137 antibody, and
- (c) an anti-CD3 antibody, an anti-CD28 antibody and an anti-CD137 antibody, and
- wherein the antigen experienced T cells expand at least 50 fold after 10 days post-activation.
A method for increasing the percentage of Th17 cells present in a T cell population, the method comprising contacting a population of T cells with at least one cytokine and with an antibody combination selected from the group consisting of:
- (a) an anti-CD3 antibody and an anti-CD5 antibody,
- (b) an anti-CD3 and an anti-CD28 antibody,
- (c) an anti-CD3 and an anti-CD238 antibody,
- (d) an anti-CD3 antibody, an anti-CD28 antibody and an anti-CD238 antibody,
- (e) an anti-CD3 antibody, an anti-CD5 antibody and an anti-CD238 antibody,
- (f) an anti-CD3 antibody, an anti-CD5 antibody and an anti-CD28 antibody, and
- (g) an anti-CD3 antibody, an anti-CD5 antibody, an anti-CD28 antibody and an anti-CD238 antibody, and
- wherein the T cell surface receptor agonists remain in contact with the population of T cells for a period of 1 to 5 days.
Dependencies are inferred from the claim text.